We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| AbbVie Inc | NYSE:ABBV | NYSE | Common Stock |
| Price Change | % Change | Share Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|
| 2.83 | 1.55% | 185.00 | 186.85 | 182.11 | 183.85 | 6,948,834 | 01:00:00 |
From Jul 2023 to Jul 2024
By Colin Kellaher
Shares of ImmunoGen took flight in premarket trading Thursday after the pharmaceutical company agreed to be acquired by biopharmaceuticals giant AbbVie at a rich premium.
Under the roughly $10.1 billion deal, AbbVie will pay $31.26 a share in cash for ImmunoGen, some 95% above Wednesday's closing price and more than 50% above the stock's 52-week high of $20.69 reached in July.
ImmunoGen shares were recently up 81% to $29.03 in premarket trading.
The deal is slated to close in the middle of 2024.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
November 30, 2023 08:27 ET (13:27 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
1 Year AbbVie Chart |
1 Month AbbVie Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
